Eli Lilly filed six lawsuits on Aug. 12 against sellers it accuses of trafficking retatrutide, an experimental weight-loss compound that no drug regulator anywhere in the world has approved [1]. The defendants are Striker Pharmacy, Aesthetic Envy, Astra Peptides, Legendary Peptides, Texas Peptides, and Lone Star Peptide [1].
Retatrutide is one of Lilly's own investigational GLP-1 drugs. It has cleared no regulatory agency on the planet, and Lilly does not plan to submit it to the U.S. Food and Drug Administration until 2027 [1]. That gap between the drug's fame and its legal status is the whole story: a market has formed around a molecule that is not yet a product.
Several of the defendants marketed retatrutide as a research-use-only product, according to the complaints, while the compound was in fact sold for human use [1]. Lilly frames the sellers in blunt terms. "These 'medical spas,' 'wellness clinics,' and self-styled suppliers are not practicing medicine; they are selling illegal drugs," the company said [1]. Lilly also says black-market vendors "openly sell retatrutide as a weight-loss 'hack'" despite the absence of any approval [1].
The suits are one front in a larger enforcement push that Lilly describes in numbers. The company says it has referred more than 200 people and entities to regulators, licensing boards, and law enforcement, and has flagged more than 14,000 websites, advertisements, social-media posts, and product listings across more than 100 countries [1]. Those are Lilly's own figures, not counts verified in court.
What the lawsuits reach for is ordinary commercial law rather than a drug-safety verdict. The claims center on trademark infringement and the illegal sale of an unapproved drug, tools a company can wield without waiting for a federal agency to act [1]. For a buyer, the practical warning is simpler than any docket: retatrutide bought from a peptide vendor or a spa is an unapproved compound, frequently sourced, Lilly alleges, from unregulated foreign manufacturers, with no regulator standing behind its contents or its dose [1].
